A process model account of the role of dopamine in intertemporal choice.
amisulpride
delay discounting
dopamine
drift diffusion model
human
neuroscience
proximity
reward
Journal
eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614
Informations de publication
Date de publication:
08 03 2023
08 03 2023
Historique:
received:
27
09
2022
accepted:
27
02
2023
entrez:
8
3
2023
pubmed:
9
3
2023
medline:
11
3
2023
Statut:
epublish
Résumé
Theoretical accounts disagree on the role of dopamine in intertemporal choice and assume that dopamine either promotes delay of gratification by increasing the preference for larger rewards or that dopamine reduces patience by enhancing the sensitivity to waiting costs. Here, we reconcile these conflicting accounts by providing empirical support for a novel process model according to which dopamine contributes to two dissociable components of the decision process, evidence accumulation and starting bias. We re-analyzed a previously published data set where intertemporal decisions were made either under the D2 antagonist amisulpride or under placebo by fitting a hierarchical drift diffusion model that distinguishes between dopaminergic effects on the speed of evidence accumulation and the starting point of the accumulation process. Blocking dopaminergic neurotransmission not only strengthened the sensitivity to whether a reward is perceived as worth the delay costs during evidence accumulation (drift rate) but also attenuated the impact of waiting costs on the starting point of the evidence accumulation process (bias). In contrast, re-analyzing data from a D1 agonist study provided no evidence for a causal involvement of D1R activation in intertemporal choices. Taken together, our findings support a novel, process-based account of the role of dopamine for cost-benefit decision making, highlight the potential benefits of process-informed analyses, and advance our understanding of dopaminergic contributions to decision making.
Identifiants
pubmed: 36884013
doi: 10.7554/eLife.83734
pii: 83734
pmc: PMC9995109
doi:
pii:
Substances chimiques
Dopamine
VTD58H1Z2X
Dopamine Agents
0
Amisulpride
8110R61I4U
Banques de données
ClinicalTrials.gov
['NCT03181841']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023, Soutschek and Tobler.
Déclaration de conflit d'intérêts
AS, PT No competing interests declared
Références
Psychopharmacology (Berl). 2009 Jul;205(1):119-28
pubmed: 19337725
Nat Neurosci. 2010 May;13(5):538-9
pubmed: 20348919
Psychopharmacology (Berl). 2011 Aug;216(3):305-21
pubmed: 21373791
Biol Psychiatry. 2020 Apr 1;87(7):678-685
pubmed: 31668477
Behav Res Methods. 2014 Mar;46(1):15-28
pubmed: 23959766
Exp Clin Psychopharmacol. 2008 Apr;16(2):113-23
pubmed: 18489015
Physiol Rev. 1998 Jan;78(1):189-225
pubmed: 9457173
Psychopharmacology (Berl). 2018 Sep;235(9):2619-2629
pubmed: 29955899
J Exp Psychol Gen. 2014 Aug;143(4):1489-514
pubmed: 24635188
Nat Hum Behav. 2019 Apr;3(4):383-392
pubmed: 30971787
Psychon Bull Rev. 2019 Apr;26(2):661-668
pubmed: 30838528
Science. 2004 Oct 15;306(5695):503-7
pubmed: 15486304
J Pharmacol Exp Ther. 1997 Jan;280(1):83-97
pubmed: 8996185
Psychon Bull Rev. 2019 Aug;26(4):1099-1121
pubmed: 30924057
Neuropsychopharmacology. 2020 Apr;45(5):780-785
pubmed: 31962344
Transl Psychiatry. 2016 Jul 05;6(7):e850
pubmed: 27378550
Neurosci Biobehav Rev. 2021 Jan;120:123-158
pubmed: 33202256
Trends Neurosci. 2015 Jun;38(6):345-52
pubmed: 25959611
Prog Neuropsychopharmacol Biol Psychiatry. 2020 Jul 13;101:109926
pubmed: 32171904
Hum Brain Mapp. 2014 Jun;35(6):2499-506
pubmed: 24038587
Proc Natl Acad Sci U S A. 2017 Nov 7;114(45):11890-11895
pubmed: 29078303
Physiol Rev. 2015 Jul;95(3):853-951
pubmed: 26109341
Eur Neuropsychopharmacol. 2015 Jun;25(6):817-27
pubmed: 25840742
J Cogn Neurosci. 2016 May;28(5):657-67
pubmed: 26836514
Comput Psychiatr. 2017 Oct 01;1:24-57
pubmed: 29601060
Curr Opin Neurobiol. 2011 Apr;21(2):322-7
pubmed: 21333525
Psychol Methods. 2017 Jun;22(2):361-381
pubmed: 28594228
Front Integr Neurosci. 2018 Feb 13;12:6
pubmed: 29487508
Front Neurosci. 2012 Aug 10;6:116
pubmed: 22905023
Psychopharmacology (Berl). 2007 Apr;191(3):507-20
pubmed: 17031711
Behav Neurosci. 2006 Jun;120(3):497-517
pubmed: 16768602
Neurosci Biobehav Rev. 2012 Jan;36(1):64-78
pubmed: 21550365
J Exp Psychol Gen. 2013 May;142(2):573-603
pubmed: 22774788
Science. 2020 Mar 20;367(6484):1362-1366
pubmed: 32193325
Neuroimage Clin. 2016 Dec 20;13:339-348
pubmed: 28066708
J Neurosci. 2020 Oct 7;40(41):7936-7948
pubmed: 32948675
Nat Hum Behav. 2017 Nov;1(11):819-827
pubmed: 31024122
Neuroscience. 2014 Dec 12;282:156-75
pubmed: 25062777
Soc Cogn Affect Neurosci. 2017 Feb 1;12(2):311-318
pubmed: 27677943
J Neurosci. 2008 Jan 30;28(5):1208-12
pubmed: 18234898
Front Neurosci. 2013 Apr 19;7:62
pubmed: 23626521
Neuron. 2012 Nov 8;76(3):470-85
pubmed: 23141060
Curr Opin Behav Sci. 2018 Aug;22:28-34
pubmed: 29713659